Aptar Pharma

Pulmonary & Nasal Delivery96

Issue No #96 April 11th, 2019

Inside the magazine

BEST PRACTICES FOR DEVELOPING EFFECTIVE TRAINING DEVICES FOR PULMONARY HEALTHCARE

BEST PRACTICES FOR DEVELOPING EFFECTIVE TRAINING DEVICES FOR PULMONARY HEALTHCARE

Joe Reynolds discusses the current state of pulmonary drug delivery device trainers, including their value to patients, the complexities of modern design and the stringent quality requirements.

AUTOMATING UNDER UNCERTAINTY – GOOD PRACTICES

AUTOMATING UNDER UNCERTAINTY – GOOD PRACTICES

Simon Drexler discusses lessons learned and good practices when dealing with uncertainty at the various stages of automation development for drug delivery device manufacturing.

GUILLAUME BROUET, APTAR PHARMA

Guillaume Brouet

GUILLAUME BROUET, APTAR PHARMA

Guillaume Brouet talks with ONdrugDelivery Magazine about how Aptar Pharma uses its device development expertise and infrastructure to provide its pharmaceutical company customers a comprehensive services offering around device development, global regulatory approval and commercialisation.

THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT

THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT

David Belton discusses the meaning of quality by design in novel respiratory drug delivery device development. He covers how, with more novel devices, prior knowledge may be insufficient for a standard FMEA-style risk analysis, and alternate science-based methods, such as functional mapping and knowledge scoring, can help in achieving QbD.

RDD ASIA 2018 CONFERENCE REVIEW AND UPCOMING RDD EVENTS

CONFERENCE SHOWCASE

RDD ASIA 2018 CONFERENCE REVIEW AND UPCOMING RDD EVENTS

RDD showcases its three biennial conferences – RDD (the North American event), RDD Europe and RDD Asia, which have become a series of must-attend events for researchers, product developers and vendors concerned with all aspects of nasal and inhaled pharmaceuticals.

PAUL ALLSOP, MILES KOTTMAN, HANNAH PRIESTLY & JON REED, CONSORT GROUP

Bespak by Recipharm

PAUL ALLSOP, MILES KOTTMAN, HANNAH PRIESTLY & JON REED, CONSORT GROUP

Consort Medical's Paul Allsop, Miles Kottman, Hannah Priestly and Jon Reed talk with ONdrugDelivery Magazine about the company’s integrated formulation and device offering, and focus on its simple, low-cost, single unit-dose, spring powered nasal device, Unidose Xtra.

130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC

130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC

Todd Pizitz and Donald Mealing discuss the ongoing opioid crisis in the US and the current use of the opioid reversal medication naxalone, and introduce the CounterAct device for naxalone home use.

IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?

IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?

Igor Gonda covers the field of nasal and pulmonary delivery of biologics, considers past failures and successes, and proposes answers to the challenges faced, from biological, biopharmaceutical and commercial standpoints.

DEPOSITION IN THREE NASAL CAST MODELS USING RETRONOSE CONCEPT

Dr Laurent Vecellio

University of Tours

DEPOSITION IN THREE NASAL CAST MODELS USING RETRONOSE CONCEPT

Laurent Vecellio, Déborah Le Pennec, Guillaume Grevin and Alain Regard discuss a study conducted to test particle deposition characteristics of the RetroNose device prototype for nasal drug delivery.

2019 ISAM CONGRESS PREVIEW

CONFERENCE SHOWCASE

Dr Barbara Rothen-Rutishauser

ISAM - International Society of Aerosols in Medicine

2019 ISAM CONGRESS PREVIEW

Prof Dr Barbara Rothen-Rutishause previews the 22nd Congress of the International Society for Aerosols in Medicine (ISAM), which will be held in Montreux, Switzerland, from May 25-29, 2019.

BK814 The Unidose™ Xtra nasal spray device: designed for simplicity

Bespak by Recipharm

BK814 The Unidose™ Xtra nasal spray device: designed for simplicity

In this Video Consort Medical's Bespak division introduces its single dose Unidose™ Xtra nasal spray device offers unique performance advantages through the use of IP-protected mechanisms that control device actuation and aqueous drug delivery.